INTEGRA LIFESCIENCES HOLDINGS CORP 10-Q

Item 1. Financial Statements INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) (Dollars in thousands, except per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Total revenue, net $ 402,062 $ 380,834 $ 1,200,320 $ 1,167,881 Costs and expenses: Cost of goods sold 195,071 180,596 589,565 534,892 Research and development 22,456 27,435 74,181 84,167 Selling, general and administrative 169,046 177,193 530,433 538,463 Intangible asset amortization 3,728 3,760 11,186 17,575 Goodwill impairment charge — — 511,365 — Total costs and expenses 390,301 388,984 1,716,730 1,175,097 Operating income (loss) 11,761 ( 8,150 ) ( 516,410 ) ( 7,216 ) Interest income 4,982 5,049 14,112 15,147 Interest expense ( 22,725 ) ( 19,373 ) ( 62,582 ) ( 51,648 ) Other (expense) income, net ( 842 ) 2,112 ( 2,932 ) 2,939 Loss before income taxes ( 6,824 ) ( 20,362 ) ( 567,812 ) ( 40,778 ) Benefit for income taxes ( 1,420 ) ( 9,667 ) ( 53,042 ) ( 14,399 ) Net loss $ ( 5,404 ) $ ( 10,695 ) $ ( 514,770 ) $ ( 26,379 ) Net loss per share Basic and diluted $ ( 0.07 ) $ ( 0.14 ) $ ( 6.72 ) $ ( 0.34 ) Weighted average common shares outstanding (See Note 13): Basic and diluted 76,753 76,448 76,637 77,196 Comprehensive loss (See Note 14) ( 6,472 ) ( 16,823 ) ( 519,174 ) $ ( 36,126 ) The accompanying unaudited notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Dollars in thousands, except per share amounts) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 232,186 $ 246,375 Short-term investments 35,693 27,192 Trade accounts receivable, net of allowances of $ 5,637 and $ 6,917 262,160 272,370 Inventories, net 489,106 429,090 Prepaid expenses 94,111 77,001 Other current assets 30,326 29,653 Total current assets 1,143,582 1,081,681 Property, plant and equipment, net 437,367 405,723 Right of use asset - operating leases 138,187 144,042 Intangible assets, net 1,160,145 1,207,588 Goodwill 615,199 1,096,952 Deferred tax assets, net 109,728 34,923 Other assets 42,244 66,515 Total assets $ 3,646,452 $ 4,037,424 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Current portion of borrowings under senior credit facility $ 38,750 $ 33,906 Current portion of lease liability - operating leases 13,826 14,540 Convertible securities — 573,170 Accounts payable, trade 92,305 82,502 Contract liabilities 11,326 10,483 Accrued compensation 74,987 85,617 Accrued expenses and other current liabilities 132,860 121,908 Total current liabilities 364,054 922,126 Long-term borrowings under senior credit facility 1,708,851 1,087,917 Long-term borrowings under securitization facility 83,500 108,100 Lease liability - operating leases 160,933 166,930 Deferred tax liabilities 58,285 60,833 Other liabilities 233,255 146,238 Total liabilities 2,608,878 2,492,144 Stockholders’ equity: Preferred stock; no par value; 15,000 authorized shares; none outstanding — — Common stock; $ 0.01 par value; 240,000 authorized shares; 92,251 and 91,610 issued at September 30, 2025 and December 31, 2024, respectively 923 916 Additional paid-in capital 1,333,506 1,323,431 Treasury stock, at cost; 14,416 shares and 14,445 shares at September 30, 2025 and December 31, 2024, respectively ( 690,025 ) ( 691,411 ) Accumulated other comprehensive loss ( 31,975 ) ( 27,571 ) Retained earnings 425,145 939,915 Total stockholders’ equity 1,037,574 1,545,280 Total liabilities and stockholders’ equity $ 3,646,452 $ 4,037,424 The accompanying unaudited notes are an integral part of these condensed consolidated financial statements. 4 Table of Contents INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (Dollars in thousands) Nine Months Ended September 30, 2025 2024 OPERATING ACTIVITIES: Net loss $ ( 514,770 ) $ ( 26,379 ) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation and amortization 113,402 103,304 Non-cash impairment charges 511,365 12,173 Deferred income tax benefit ( 55,316 ) ( 13,743 ) Share-based compensation 12,745 17,225 Amortization of debt issuance costs and expenses associated with debt refinancing 4,590 4,193 Non-cash lease expense ( 906 ) ( 129 ) Loss on disposal of property and equipment 490 1,337 Change in fair value of contingent consideration and others ( 14,644 ) ( 319 ) Changes in assets and liabilities: Accounts receivable 15,967 38,861 Inventories ( 43,419 ) ( 27,579 ) Prepaid expenses and other current assets ( 4,994 ) ( 34,401 ) Other non-current assets 3,335 ( 1,745 ) Accounts payable, accrued expenses and other current liabilities 3,704 2,686 Contract liabilities 2,715 1,822 Other non-current liabilities 4,304 1,336 Net cash provided by operating activities 38,568 78,642 INVESTING ACTIVITIES: Purchases of property and equipment ( 64,222 ) ( 74,818 ) Cash paid for business acquisitions, net of cash acquired — ( 281,994 ) Purchases of short-term investments ( 8,502 ) ( 48,997 ) Proceeds from maturities of short-term investments — 19,250 Net payments from swaps designated as net investment hedges ( 432 ) — Net cash used in investing activities ( 73,156 ) ( 386,559 ) FINANCING ACTIVITIES: Proceeds from borrowings of long-term indebtedness 671,000 451,100 Payments on debt ( 69,819 ) ( 147,188 ) Repayments of convertible debt ( 574,983 ) — Payment of debt issuance costs ( 3,930 ) — Purchases of treasury stock ( 221 ) ( 50,000 ) Payments for contingent considerations ( 16,451 ) ( 11,923 ) Proceeds from exercised stock options 957 6,398 Cash taxes paid in net equity settlement ( 2,560 ) ( 3,374 ) Net cash provided by financing activities 3,993 245,013 Effect of exchange rate changes on cash and cash equivalents 16,406 1,659 Net decrease in cash and cash equivalents ( 14,189 ) ( 61,245 ) Cash and cash equivalents at beginning of period 246,375 276,402 Cash and cash equivalents at end of period $ 232,186 $ 215,157 The accompanying unaudited notes are an integral part of these condensed consolidated financial statements. 5 Table of Contents INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED) (Dollars in thousands) Nine Months Ended September 30, 2025 Common Stock Treasury Stock Additional Paid-In Capital Accumulated Other Comprehensive Loss Retained Earnings Total Equity Shares Amount Shares Amount Balance, January 1, 2025 91,609 $ 916 ( 14,445 ) $ ( 691,411 ) $ 1,323,431 $ ( 27,571 ) $ 939,915 $ 1,545,280 Net loss — — — — — — ( 25,293 ) ( 25,293 ) Other comprehensive income, net of tax — — — — — 3,465 — 3,465 Issuance of common stock through employee stock purchase plan 44 — — — 957 — — 957 Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures 483 5 21 1,032 ( 3,167 ) — — ( 2,130 ) Share-based compensation — — — 1,860 — — 1,860 Balance, March 31, 2025 92,136 $ 921 ( 14,424 ) $ ( 690,379 ) $ 1,323,081 $ ( 24,106 ) $ 914,622 $ 1,524,139 Net loss — — — — — — ( 484,073 ) ( 484,073 ) Other comprehensive loss, net of tax — — — — — ( 6,801 ) — ( 6,801 ) Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures 201 2 8 345 ( 571 ) — — ( 224 ) Share-based compensation — — — — 5,341 — — 5,341 Other Adjustments — $ — — — 279 $ — $ — 279 Balance, June 30, 2025 92,337 $ 923 ( 14,416 ) $ ( 690,034 ) $ 1,328,130 $ ( 30,907 ) $ 430,549 $ 1,038,661 Net loss — — — — — — ( 5,404 ) ( 5,404 ) Other comprehensive loss, net of tax — — — — — ( 1,068 ) — ( 1,068 ) Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures ( 86 ) — — 9 ( 207 ) — — ( 198 ) Share-based compensation — — — — 5,583 — — 5,583 Balance, September 30, 2025 92,251 $ 923 ( 14,416 ) $ ( 690,025 ) $ 1,333,506 $ ( 31,975 ) $ 425,145 $ 1,037,574 6 Table of Contents Nine Months Ended September 30, 2024 Common Stock Treasury Stock Additional Paid-In Capital Accumulated Other Comprehensive Loss Retained Earnings Total Equity Shares Amount Shares Amount Balance, January 1, 2024 90,920 $ 909 ( 12,751 ) $ ( 647,262 ) $ 1,302,484 $ ( 15,106 ) $ 946,859 $ 1,587,884 Net loss — — — — — — ( 3,281 ) ( 3,281 ) Other comprehensive income, net of tax — — — — — 4,460 — 4,460 Issuance of common stock through employee stock purchase plan 23 — — — 965 — — 965 Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures 541 2 16 840 1,470 — — 2,312 Share-based compensation — 4 — — 5,608 — — 5,612 Balance, March 31, 2024 91,484 $ 915 ( 12,735 ) $ ( 646,422 ) $ 1,310,527 $ ( 10,646 ) $ 943,578 $ 1,597,952 Net income — — — — — — ( 12,402 ) ( 12,402 ) Other comprehensive loss, net of tax — — — — — ( 8,080 ) — ( 8,080 ) Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures 107 1 — 20 ( 101 ) — — ( 80 ) Share-based compensation — — — — 7,305 — — 7,305 Accelerated shares repurchased — — ( 1,273 ) ( 34,351 ) ( 16,149 ) — — ( 50,500 ) Balance, June 30, 2024 91,591 916 ( 14,008 ) ( 680,753 ) 1,301,582 ( 18,726 ) 931,176 1,534,195 Net income — — — — — — ( 10,695 ) ( 10,695 ) Other comprehensive income, net of tax — — — — — ( 6,128 ) — ( 6,128 ) Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures ( 3 ) — — 10 ( 181 ) — — ( 171 ) Share-based compensation — — — — 4,386 — — 4,386 Accelerated shares repurchased — — ( 446 ) ( 11,067 ) 11,067 — — — Balance, September 30, 2024 91,588 916 ( 14,454 ) ( 691,810 ) 1,316,854 ( 24,854 ) 920,481 1,521,587 The accompanying unaudited notes are an integral part of these condensed consolidated financial statements. 7 Table of Contents INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 1. BASIS OF PRESENTATION General The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise. In the opinion of management, the September 30, 2025 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholders’ equity, results of operations and cash flows of the Company for the periods presented. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2024 included in the Company’s Annual Report on Form 10-K. The consolidated balance sheet as of December 31, 2024 was derived from audited financial statements, but does not include all disclosures required by GAAP. Operating results for the three and nine-month period ended September 30, 2025 are not necessarily indicative of the results to be expected for the entire year. The preparation of consolidated financial statements is in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the unaudited condensed consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. Recent Accounting Pronouncements In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2024. The amendments should be applied on a prospective basis. Retrospective application to all prior periods presented in the financial statements is permitted. The Company will adopt ASU 2023-09 for the annual period ending on December 31, 2025 on a prospective basis. The Company is currently evaluating the impact that the adoption of this guidance will have on its disclosures. In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), and in January 2025, the FASB issued ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date (“ASU 2025-01”). ASU 2024-03 requires additional disclosure of the nature of expenses included in the income statement. The standard requires disclosures about specific types of expenses included in the expense captions presented in the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The requirements should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its disclosures. 8 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (“ASU 2025-06”), which removes all references to software development project stages and requires entities to start capitalizing software costs when both of the following occur: (i) management has authorized and committed to funding the software project and (ii) it is probable that the project will be completed and the software will be used to perform the function intended. This ASU is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years, with early adoption permitted as of the beginning of a fiscal year. The amendments may be applied prospectively, retrospectively, or via a modified prospective transition method. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements. There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company’s financial position, results of operations, or cash flows. Cash and cash equivalents The Company had cash and cash equivalents, primarily consisting of cash on-hand, as well as time deposits with original maturities of three months or less and money market funds, which are highly liquid and readily convertible to cash, totaling approximately $ 232.2 million and $ 246.4 million at September 30, 2025 and December 31, 2024, respectively. Short-term investments The Company had short-term investments, primarily consisting of time deposits with original maturities between three months and one year, totaling approximately $ 35.7 million and $ 27.2 million at September 30, 2025 and December 31, 2024, respectively. The short-term investments are valued based on Level 1 measurements in the fair value hierarchy. Employee termination benefits The Company does not have a written severance plan but has a history of providing benefits for employees in the case of involuntary termination. In situations outside the U.S., there are minimum statutory termination benefits requirements by country that must be paid to the affected employees. The Company records employee severance costs associated with these restructuring activities in accordance with the authoritative guidance for non-retirement post-employment benefits. Charges associated with these activities are recorded when the payment of benefits is probable and can be reasonably estimated. In situations where the Company pays out termination benefits in excess of statutory minimum amounts based on management’s discretion, the Company records these termination costs once communication is made to the affected employees. The timing of the recognition of charges for employee severance costs other than minimum statutory benefits depends on whether the affected employees are required to render service beyond their legal notification period in order to receive the benefits. If affected employees are required to render service beyond their legal notification period, charges are recognized over the future service period. Otherwise, charges are recognized when management has approved a specific plan and employee communication requirements have been met. The Company incurred employee termination costs on restructuring activities in the consolidated statement of operations for the nine months ended September 30, 2025 and 2024. The following table summarizes the activity in the restructuring related accrual balances included within accrued expenses and other current liabilities in the consolidated balance sheet for the nine months ended September 30, 2025 and 2024. Nine Months Ended September 30, (Dollars in thousands) 2025 2024 Balance, beginning of the year $ 5,151 $ 2,113 Charges: Cost of Goods Sold 113 — Research and development 417 — Selling, general and administrative 6,780 — Payments and other adjustments ( 8,129 ) ( 1,691 ) Balance, end of the period $ 4,332 $ 422 9 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) 2. ACQUISITIONS AND DIVESTITURES Acquisition of Durepair® On October 2, 2024, the Company completed the acquisition of the product rights for Durepair Regeneration Matrix (“Durepair”), a non-synthetic dura substitute for repair of the dura mater during neurosurgical procedures, from Medtronic plc for total consideration of $ 45.0 million. The Company made cash payments of $ 10.0 million upon the closing of the acquisition in October 2024, $ 15.0 million on the first anniversary of the acquisition in October 2025, and will make an additional cash payment of $ 20.0 million upon the second anniversary of the acquisition in October 2026. The additional cash payments in October 2025 and October 2026 are included at present value in accrued expenses and other current liabilities and other liabilities, respectively, as of September 30, 2025. The acquisition of the product rights for Durepair, which consist of certain patents and trademarks, regulatory approvals, and other records, has been accounted for as an asset acquisition in accordance with FASB Topic 805, Business Combinations (“ASC 805”) as the acquisition does not include an assembled workforce and substantially all of the fair value of the assets acquired is concentrated in a single identifiable intangible asset. Acquisition of Acclarent, Inc. On April 1, 2024, the Company completed the acquisition of all of the outstanding capital stock of Acclarent, Inc. (“Acclarent”), a developer and marketer of medical devices used in ear, nose, throat (“ENT”) procedures, from Ethicon, Inc., a subsidiary of Johnson & Johnson, for approximately $ 282.0 million in cash, subject to customary adjustments set forth in the purchase agreement related to working capital balances transferred to the Company. In the second half of 2024, the Company finalized and settled the working capital adjustment in the amount of $ 4.2 million, which resulted in a reduction to goodwill and also recognized a measurement period adjustment to recognize deferred tax liabilities of $ 1.1 million with a corresponding increase to goodwill as a result of a change to the estimated deferred tax rate applied and the book-to-tax difference associated with fixed assets acquired. The addition of Acclarent’s ENT product portfolio, including sinus balloon dilation, eustachian tube balloon dilation, and surgical navigation systems technologies, and dedicated salesforce enhanced the Company’s position in the ENT specialty device market. Acclarent’s results of operations have been reported in the Company’s Codman Specialty Surgical reportable segment from the date of acquisition. Assets Acquired and Liabilities Assumed at Fair Value The Acclarent acquisition has been accounted for using the acquisition method of accounting in accordance with ASC 805. This method requires that assets acquired and liabilities assumed in a business combination are recognized at their fair values as of the acquisition date. 10 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date: Dollars in thousands Estimated Fair Value Estimated Useful Life Current assets: Cash $ — Trade accounts receivable, net of allowances of $ 3,885 23,716 Inventories, net 20,294 Prepaid expenses 273 Other current assets 476 Total current assets $ 44,759 Property, plant and equipment, net 7,716 Right of use asset - operating leases 989 Intangible assets, net Completed technology 202,000 12 years Trademarks/brand names 3,000 5 years All other 17,000 4 years Goodwill 62,482 Deferred tax assets 6,895 Total assets acquired $ 344,841 Current liabilities: Accounts payable, trade 3,989 Contract liabilities 3,984 Accrued compensation 1,037 Accrued expenses and other current liabilities 2,278 Current portion of lease liability - operating leases 365 Total current liabilities $ 11,653 Lease liability - operating leases 624 Deferred tax liabilities 54,753 Total liabilities assumed 67,030 Net assets acquired $ 277,811 The carrying value of trade accounts receivable, prepaid expenses, other current assets, accounts payable, contract liabilities, accrued compensation, accrued expenses and other current liabilities, as well as certain other current and non-current assets and liabilities, generally represented the fair value at the date of acquisition. Intangible Assets The estimated fair value of the intangible assets acquired was determined using the multi-period, excess earnings method of the income approach, which estimates value based on the present value of future economic benefits attributable to the intangible assets. The significant assumptions used in developing the valuation included the estimated annual net cash flows including application of revenue growth rates, cost of sales, the discount rate that appropriately reflects the risk inherent in each future cash flow stream, obsolescence rate, and an assessment of the asset’s life cycle, as well as other factors. The assumptions used in the financial forecasts were based on historical data, supplemented by current and anticipated growth rates, management plans, and market-comparable information. Fair value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors. The intangible assets acquired have a weighted average useful life of 11 years. The Company used a discount rate of 12.2 % to arrive at the present value for the acquired intangible assets to reflect the rate of return a market participant would expect to earn and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results. 11 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) Goodwill Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected synergies of the combined company and assembled workforce. Goodwill has been allocated to the Codman Specialty Surgical segment, as shown in Note 5. Goodwill and Other Intangible Assets . Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes. Deferred Tax Liabilities Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions. 3. REVENUES FROM CONTRACTS WITH CUSTOMERS Summary of Accounting Policies on Revenue Recognition Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services. Performance Obligations The Company’s performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers. Significant Estimates Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company’s strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant. The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract. The Company’s return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days. The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers. Contract Assets and Liabilities Revenues recognized from the Company’s private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the prepaid expenses and other current assets account in the consolidated balance sheet. Upon invoicing to the customer, the balance is recorded in trade receivable, net in the consolidated balance sheet. Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability. 12 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) The following table summarizes the changes in the contract asset and liability balances for the nine months ended September 30, 2025: Dollars in thousands Total Contract Asset Contract asset, January 1, 2025 $ 6,146 Transferred to trade receivables from contract asset included in beginning of the year contract asset $ ( 6,146 ) Contract asset, net of transferred to trade receivables on contracts during the period $ 4,928 Contract asset, September 30, 2025 $ 4,928 Contract Liability Contract liability, January 1, 2025 $ 19,669 Recognition of revenue included in beginning of year contract liability $ ( 8,452 ) Contract liability, net of revenue recognized on contracts during the period $ 11,008 Foreign currency translation $ 123 Contract liability, September 30, 2025 $ 22,348 As of September 30, 2025, the short-term portion of the contract liability of $ 11.3 million, representing 51 % of unsatisfied or partially unsatisfied performance obligations, is expected to be recognized as revenue within 12 months and is included in current liabilities in the consolidated balance sheet. The long-term portion of $ 11.0 million, representing the remaining balance to be recognized thereafter, is included in other liabilities in the consolidated balance sheet. Shipping and Handling Fees The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold. Product Warranties Certain of the Company’s medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet. Taxes Collected from Customers The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer. 13 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) Disaggregated Revenue The following table presents revenues disaggregated by the major sources of revenues for the three and nine months ended September 30, 2025 and 2024 (dollar amounts in thousands): Three Months Ended September 30, 2025 Three Months Ended September 30, 2024 Nine Months Ended September 30, 2025 Nine Months Ended September 30, 2024 Neurosurgery $ 201,563 $ 175,956 $ 601,466 $ 583,726 Instruments 50,151 54,238 154,181 153,148 ENT 40,869 40,588 121,557 92,103 Total Codman Specialty Surgical 292,583 270,782 877,204 828,977 Wound Reconstruction and Care 83,988 80,460 243,514 249,032 Private Label 25,491 29,592 79,602 89,872 Total Tissue Technologies 109,479 110,052 323,116 338,904 Total revenue $ 402,062 $ 380,834 $ 1,200,320 $ 1,167,881 See Note 15. Segment and Geographic Information , for details of revenues based on the location of the customer. 4. INVENTORIES Inventories, net consisted of the following: Dollars in thousands September 30, 2025 December 31, 2024 Finished goods $ 258,774 $ 223,729 Work in process 100,010 79,423 Raw materials 130,322 125,938 Total inventories, net $ 489,106 $ 429,090 5. GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill Changes in the carrying amount of goodwill for the nine-month period ended September 30, 2025 were as follows: Dollars in thousands Codman Specialty Surgical Tissue Technologies Total Goodwill at December 31, 2024 $ 715,730 $ 381,222 $ 1,096,952 Impairment ( 388,106 ) ( 123,259 ) ( 511,365 ) Foreign currency translation 16,567 13,045 29,612 Goodwill at September 30, 2025 $ 344,191 $ 271,008 $ 615,199 In accordance with FASB Topic 350, Intangibles—Goodwill and Other (“ASC 350”), goodwill is not subject to amortization but is tested for impairment at the reporting unit level annually in the third quarter. Additionally, the Company may perform interim tests of goodwill for impairment if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. An impairment loss is recognized when the reporting unit’s carrying amount exceeds its estimated fair value. The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including reporting unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative evaluation for some or all of its reporting units and perform a quantitative test. The quantitative test uses a combination of both an income approach and a market approach to determine the fair value of the reporting unit. The income approach utilizes the estimated discounted cash flows for the reporting unit, while the market approach utilizes comparable publicly-traded companies’ revenue and earnings 14 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) before interest, taxes, depreciation, and amortization (“EBITDA”) multiples. Estimates and assumptions used in the income approach to calculate projected future discounted cash flows included revenue growth rates, cost of sales, terminal growth rates, and a discount rate for each reporting unit. Discount rates are determined using a weighted average cost of capital for risk factors specific to each reporting unit and other market and industry data. The assumptions used are inherently subject to uncertainty and slight changes in these assumptions could have a significant impact on the concluded value. The estimates and assumptions applied represent a Level 3 measurement in the fair value hierarchy. Level 3 inputs are supported by limited or no market activity and reflect the Company’s assumptions in measuring fair value. During the second quarter of 2025, the Company performed a quantitative assessment of its Tissue Technologies, Neurosurgery, and Instruments and ENT reporting units in accordance with ASC 350 due to the decrease in the price per share of the Company’s common stock related to a number of factors including recent tariff changes that have created broad economic uncertainty and the impact of quality, operational, and supply issues. The Company recognized an aggregate charge of $ 511.4 million in goodwill impairment expense in the consolidated statement of operations in the second quarter of 2025. The quantitative test for the Tissue Technologies reporting unit utilized a terminal growth rate of 2.5 % and a discount rate of 13.5 % in the income approach. The Company determined, after performing the quantitative analysis, that the fair value of the Tissue Technologies reporting unit was less than its carrying amount and recognized an impairment of $ 123.3 million. The quantitative test for the Neurosurgery reporting unit utilized a terminal growth rate of 2.5 % and a discount rate of 13.5 % in the income approach. The Company determined, after performing the quantitative analysis, that the fair value of the Neurosurgery reporting unit was less than its carrying amount and recognized an impairment of $ 249.0 million. The quantitative test for the Instruments and ENT reporting unit utilized a terminal growth rate of 2.5 % and a discount rate of 12.0 % in the income approach. The Company determined, after performing the quantitative analysis, that the fair value of the Instruments and ENT reporting unit was less than its carrying amount and recognized an impairment of $ 139.1 million. In the third quarter of 2025, the Company performed its annual test of its reporting units for impairment and completed a qualitative evaluation of its Tissue Technologies and Neurosurgery reporting units. The Instruments and ENT reporting unit had been deemed fully-impaired during the second quarter of 2025 and was excluded from this evaluation. After performing the qualitative analysis, the Company concluded that it was more likely than not that the fair values of the Tissue Technologies and Neurosurgery reporting units were greater than their carrying amounts. Therefore, it was not necessary to perform a quantitative impairment test. The Company did not recognize any goodwill impairment charges during 2024. Other Intangible Assets The components of the Company’s identifiable intangible assets were as follows: September 30, 2025 Dollars in thousands Weighted Average Life Cost Accumulated Amortization Net Completed technology 17 years $ 1,484,605 $ ( 608,295 ) $ 876,310 Customer relationships 12 years 169,246 ( 143,789 ) 25,457 Trademarks/brand names 27 years 103,340 ( 46,639 ) 56,701 Codman tradename Indefinite 179,516 — 179,516 Supplier relationships 30 years 30,211 ( 19,860 ) 10,351 All other 6 years 23,428 ( 11,618 ) 11,810 $ 1,990,346 $ ( 830,201 ) $ 1,160,145 December 31, 2024 Dollars in thousands Weighted Average Life Cost Accumulated Amortization Net Completed technology 17 years $ 1,452,545 $ ( 525,959 ) $ 926,586 Customer relationships 12 years 166,038 ( 137,186 ) 28,852 Trademarks/brand names 27 years 99,951 ( 42,173 ) 57,778 Codman tradename Indefinite 168,202 — 168,202 Supplier relationships 30 years 30,211 ( 19,126 ) 11,085 All other 6 years 22,820 ( 7,735 ) 15,085 $ 1,939,767 $ ( 732,179 ) $ 1,207,588 15 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) Intangible Assets with Indefinite Lives The Company does not amortize intangible assets with indefinite lives but tests its intangible assets with indefinite lives for impairment annually in the third quarter in accordance with ASC 350. Additionally, the Company performs interim tests of its intangible assets with indefinite lives for impairment if an event occurs or circumstances change that could potentially reduce the fair value of an indefinite lived intangible asset below its carrying amount. The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of the intangible asset is less than its carrying amount. The Company may elect to bypass this qualitative evaluation and perform a quantitative test. During the second quarter of 2025 the Company performed a quantitative assessment of its Codman tradename intangible asset in accordance with ASC 350 due to the decrease in the price per share of the Company’s common stock related to a number of factors including recent tariff changes that have created broad economic uncertainty and the impact of quality, operational, and supply issues. In performing this test, the Company utilized a discount rate of 14.5 %. The assumptions used in evaluating the Codman tradename for impairment are subject to change and are tracked against historical results by management. Based on the results of the quantitative test, the Company recorded no impairment to the Codman tradename intangible asset. In the third quarter of 2025, the Company performed its annual test of its intangible assets with indefinite lives for impairment and completed a qualitative evaluation of its Codman tradename intangible asset. After performing the qualitative analysis, the Company concluded that it was more likely than not that the fair value of the Codman tradename intangible asset was greater than its carrying amount. Therefore, it was not necessary to perform a quantitative impairment test. The Company did not recognize any impairment charges on its intangible assets with indefinite lives during 2024. Intangible Assets with Definite Lives Developed technologies and other definite-lived intangible assets are amortized over their estimated useful lives either using the straight-line method or, if reliably determinable, based on the pattern of which the economic benefit of the asset is expected to be utilized. Definite-lived intangible assets are periodically evaluated for impairment in accordance with FASB Topic 360, Property, Plant and Equipment (“ASC 360”) whenever events or changes in circumstances indicate that a definite-lived intangible asset’s carrying value may not be recoverable. Total amortization of intangible assets for the three and nine months ended September 30, 2025 was $ 26.9 million and $ 80.1 million, respectively. Of this amount, $ 23.1 million and $ 69.0 million, respectively, was related to amortization of technology based intangibles and included in cost of goods sold. Total amortization of intangible assets for the three and nine months ended September 30, 2024 was $ 25.6 million and $ 78.7 million, respectively. Of this amount, $ 21.8 million and $ 61.1 million, respectively, was related to amortization of technology based intangibles and included in cost of goods sold. $ 7.1 million related to the impairment of a customer relationship intangible and the remainder were included in intangible amortization in the statement of operations. Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of goods sold) is expected to be approximately $ 26.9 million for the remainder of 2025, $ 107.6 million in 2026, $ 106.5 million in 2027, $ 103.0 million in 2028, $ 97.7 million in 2029, $ 91.6 million in 2030 and $ 447.6 million thereafter. In the first quarter of 2024, due to third-party audit findings and an update to the estimated timeframe to resume the commercial distribution of products manufactured in the Company's manufacturing facility located in Boston, Massachusetts (the “Boston facility”), the Company elected to perform quantitative impairment testing on certain definite-lived intangible assets including completed technology and customer relationships in accordance with ASC 360. The Company recorded an impairment charge related to the definite-lived intangible asset associated with the customer relationships of $ 7.1 million in intangible asset amortization in the consolidated statement of operations. With respect to the definite-lived intangible assets associated with the completed technology of SurgiMend® and PriMatrix®, the Company determined that the carrying amount of these definite-lived intangible assets were recoverable and, therefore, the intangible assets were not deemed to be impaired. In the second quarter of 2024, the Company approved a plan to transition the commercial distribution of SurgiMend and PriMatrix from the Boston facility to the Company’s manufacturing facility in Braintree, Massachusetts (the “Braintree facility”). The Company considered the impact to the update to the estimated timeframe to resume the commercial distribution of products manufactured in the Boston facility on the assumptions used in the quantitative assessment of the definite-lived intangible assets completed in the first quarter of 2024, which did not require further evaluation for impairment. The carrying values of SurgiMend and PriMatrix are $ 27.4 million and $ 21.1 million, respectively, as of September 30, 2025. 16 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) Potential Impact of Risks and Uncertainties on Management’s Estimates The rapidly evolving tariff changes imposed by the U.S. and other countries since early 2025 have created increased risks and uncertainties surrounding the Company’s future results of operations. In 2025 President Trump has announced reciprocal tariffs on many countries and certain countries, such as China, have responded with retaliatory tariffs. In September 2025, the U.S. Department of Commerce initiated national security investigations into medical equipment, devices, and robotics. The tariff environment has continued to shift throughout the 2025 calendar year, with new measures being proposed, paused, implemented, and countered, contributing to broader trade policy uncertainty. The assumptions used by the Company in its quantitative tests of goodwill and intangible assets are inherently subject to uncertainty and slight changes in these assumptions, including the extent and duration of any subsequent changes in U.S. import tariffs and reciprocal measures by China and the resulting impact on general economic conditions and on the Company’s business, could have a significant impact on the concluded values. 6. DEBT Amendment to the Seventh Amended and Restated Credit Agreement On June 6, 2025, in response to the risks and uncertainties surrounding the Company’s future results of operations due to tariffs, the Company entered into the June 2025 Amendment of the Senior Credit Facility with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. The June 2025 Amendment did not increase the Company’s total indebtedness or extend the maturity date of the Senior Credit Facility. Under the terms of the June 2025 Amendment, the Company’s Consolidated Total Leverage Ratio (defined, as of any date of determination, as the ratio of (a) Consolidated Funded Indebtedness as of such date (as defined in the Senior Credit Facility) less cash that is not subject to any restriction on the use or investment thereof to (b) Consolidated EBITDA (as defined in the Senior Credit Facility)) for the period of four consecutive fiscal quarters ending on such date was modified to the following: Fiscal Quarter Ending Maximum Consolidated Total Leverage Ratio June 30, 2025 through June 30, 2026 5.00 to 1.00 September 30, 2026 4.75 to 1.00 December 31, 2026 4.50 to 1.00 March 31, 2027 and the last day of each fiscal quarter thereafter 4.00 to 1.00 In addition to the foregoing, from the date of the June 2025 Amendment through the fiscal quarter ending December 31, 2026 (the “Covenant Relief Period”), the Amendment, among other things, also: (i) temporarily establishes, during the Covenant Relief Period, a revised applicable rate schedule; (ii) temporarily limits, during the Covenant Relief Period, the Company’s ability to make certain investments; (iii) temporarily restricts, during the Covenant Relief Period, the Company’s ability to incur incremental indebtedness under the Senior Credit Facility, create certain liens, make certain restricted payments and incur or guarantee indebtedness of excluded subsidiaries; and (iv) temporarily prohibits, during the Covenant Relief Period, the Company from selling, transferring or exclusively licensing material intellectual property to a subsidiary of the Company that is not a loan party under the Senior Credit Facility or designating any subsidiary that owns or exclusively licenses any material intellectual property as an excluded subsidiary under the Senior Credit Facility. Borrowings under the Senior Credit Facility bear interest under the applicable rate schedule, at the Company’s option, at a rate equal to the following: i. Term SOFR in effect from time to time plus 0.10 % plus the applicable rate (ranging from 1.00 % to 2.13 % during the Covenant Relief Period and from 1.00 % to 1.75 % thereafter) or ii. The highest of: 1. the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.50 %; 2. the prime lending rate of Bank of America, N.A.; or 3. the one-month Term SOFR plus 1.00 %. 17 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) The applicable rates are based on the Company’s Consolidated Total Leverage Ratio for the period of four consecutive fiscal quarters ending on such date. The Company will pay an annual commitment fee (ranging from 0.15 % to 0.33 % during the Covenant Relief Period and from 0.15 % to 0.30 % thereafter), based on the Company’s Consolidated Total Leverage Ratio, on the amount available for borrowing under the revolving credit facility component of the Senior Credit Facility. In connection with the June 2025 Amendment, the Company incurred $ 3.9 million in fees to creditors and third parties. On March 24, 2023, the Company entered into the Senior Credit Facility with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. The Senior Credit Facility extended the maturity date to March 24, 2028, amended the contractual repayments of the term loan component, and amended the interest rate from LIBOR to SOFR-indexed interest. The Company continues to have the aggregate principal amount of up to approximately $ 2.1 billion available to it through the following facilities: (i) a $ 775 million term loan facility, and (ii) a $ 1.3 billion revolving credit facility, which includes a $ 60 million sublimit for the issuance of standby letters of credit and a $ 60 million sublimit for swingline loans. The terms of the Senior Credit Facility limit the amount of dividends the Company may pay. The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and, at September 30, 2025, the Company was in compliance with all such covenants. At September 30, 2025 and December 31, 2024, there wa s $ 1.0 billion and $ 365.0 million, respectively, ou tstanding under the revolving credit facility component of the Senior Credit Facility. At September 30, 2025 and December 31, 2024, there was $ 736.3 million and $ 760.5 million outstanding under the term loan component of the Senior Credit Facility at a weighted average interest rate of 6.4 % and 6.0 %, respectively. As of September 30, 2025 and December 31, 2024 there was $ 38.8 million and $ 33.9 million, respectively, of the term loan component of the Senior Credit Facility classified as current on the condensed consolidated balance sheet. The fair value of the term loan component and revolving credit facility component of the Senior Credit Facility at September 30, 2025 was $ 734.0 million, and $ 1,011.6 million, respectively. The fair value was determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable i nputs that reflect unadjusted quoted prices for identical assets or liabilities. As of September 30, 2025 and December 31, 2024, letters of credit outstanding to taled $ 3.0 million and $ 1.7 million, respectively. There were no amounts drawn under the letters of credit outstanding as of September 30, 2025. Contractual repayments of the term loan component of the Senior Credit Facility are due as follows: As of September 30, 2025 Principal Repayment Dollars in thousands Remainder of 2025 $ 9,688 2026 38,750 2027 53,281 2028 634,531 $ 736,250 Future interest payments on the term loan component of the Senior Credit Facility based on current interest rates are expected to approximate $ 11.8 million for the remainder of 2025, $ 45.5 million in 2026, $ 42.8 million in 2027, and $ 9.3 million in 2028. Interest is calculated on the term loan component of the Senior Credit Facility based on SOFR plus the certain amounts set forth in the Senior Credit Facility. As the revolving credit facility component of the Senior Credit Facility and Securitization Facility (defined below) can be repaid at any time, no interest has been included in the calculation. Any outstanding borrowings on the revolving credit facility component of the Senior Credit Facility are due on March 24, 2028. 18 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) Convertible Senior Notes The Company’s 0.5 % Convertible Senior Notes due 2025 (the “2025 Notes”) issued in February 2020 pursuant to an indenture, dated as of February 7, 2020 (the “Original Indenture”), between the Company and Citibank, N.A., as trustee, matured on August 15, 2025. The 2025 Notes were settled upon maturity for $ 575.0 million in cash, excluding accrued interest, funded by borrowings on the revolving credit facility component of the Senior Credit Facility. No shares were issued to settle the 2025 Notes. In connection with the issuance of the 2025 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the 2025 Notes (the “hedge participants”). The cost of the call transactions was $ 104.2 million for the 2025 Notes. The Company received $ 44.5 million of proceeds from the warrant transactions for the 2025 Notes. The call transactions involved purchasing call options from the hedge participants, and the warrant transactions involved selling call options to the hedge participants with a higher strike price than the purchased call options. The initial strike price of the call transactions was $ 73.67 , subject to anti-dilution adjustments substantially similar to those in the 2025 Notes. The initial strike price of the warrant transactions was $ 113.34 for the 2025 Notes, subject to customary anti-dilution adjustments. The call transactions entered into with the hedge participants expired in August 2025 and the warrant transactions entered into with the hedge participants expire ratably over the period from November 2025 through February 2026. Securitization Facility The Company maintains an accounts receivable securitization facility (the “Securitization Facility”) under which accounts receivable of certain domestic subsidiaries are sold on a non-recourse basis to a special purpose entity (“SPE”), which is a bankruptcy-remote, consolidated subsidiary of the Company. Accordingly, the assets of the SPE are not available to satisfy the obligations of the Company or any of its subsidiaries. From time to time, the SPE may finance such accounts receivable with a revolving loan facility secured by a pledge of such accounts receivable. The amount of outstanding borrowings on the Securitization Facility at any one time is limited to $ 150.0 million. The Securitization Facility Agreement (“Securitization Agreement”) governing the Securitization Facility contains certain covenants and termination events. An occurrence of an event of default or a termination event under this Securitization Agreement may give rise to the right of its counterparty to terminate this facility. As of September 30, 2025, the Company was in compliance with the covenants and none of the termination events had occurred. On December 15, 2023, the Company entered into an amendment (the “December 2023 Amendment”) of the Securitization Facility which extended the maturity date from May 28, 2024 to December 15, 2026. The Company incurred approximately $ 0.3 million of new issuance costs associated with the December 2023 Amendment which will be amortized over 3 years, the length of the Securitization Agreement as amended by the December 2023 Amendment. Due to the increase in borrowing capacity, the remaining $ 0.1 million of unamortized costs from the previous agreement will also be amortized over the length of the amended agreement, three years . In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility and amended the interest rate from LIBOR to SOFR-indexed rate. The December 2023 Amendment and April 2023 Amendment did not increase the Company’s total indebtedness. At September 30, 2025 and December 31, 2024, the Company had $ 83.5 million and $ 108.1 million, respectively, of outstanding borrowings under its Securitization Facility with an interest rate of 5.2 % and 5.4 %, respectively. The fair value of the outstanding borrowing of the Securitization Facility at September 30, 2025 was $ 82.0 million. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable i nputs that reflect unadjusted quoted prices for identical assets or liabilities. Debt Issuance Costs Debt issuance costs associated with the Senior Credit Facility (other than the revolving credit facility component) and the 2025 Notes are presented as a reduction to the carrying value of the related debt. Debt issuance costs associated with the revolving credit facility component of the Senior Credit Facility are capitalized within other long-term assets on the consolidated balance sheet. 19 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) Estimated Fair Value of Debt Measurements The carrying amounts and the estimated fair values of debt as of September 30, 2025 and December 31, 2024 are as follows: September 30, 2025 December 31, 2024 Fair Value Measurement Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value Dollars in thousands Senior credit facility - term loan Level 2 $ 736,250 $ 733,980 $ 760,469 $ 751,143 Senior credit facility - revolving component Level 2 1,015,000 1,011,573 365,000 360,144 2025 Notes Level 1 — — 575,000 555,594 Securitization Level 2 83,500 82,046 108,100 105,831 Subtotal $ 1,834,750 $ 1,827,599 $ 1,808,569 $ 1,772,712 Debt issuance costs ( 3,649 ) ( 5,476 ) Total debt $ 1,831,101 $ 1,827,599 $ 1,803,093 $ 1,772,712 7. DERIVATIVE INSTRUMENTS Interest Rate Hedging The Company’s interest rate risk relates to U.S. dollar denominated variable interest rate borrowings. The Company uses interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of the Company’s expected SOFR-indexed borrowings. Additionally, the Company entered into a basis swap where the Company receives Term SOFR and pays daily compounded SOFR to convert the portfolio of swaps from daily compounded SOFR to Term SOFR. The Company held the following interest rate swaps as of September 30, 2025 and December 31, 2024 (dollar amounts in thousands): September 30, 2025 December 31, 2024 September 30, 2025 December 31, 2024 Hedged Item Notional Amount Designation Date Effective Date Termination Date Fixed Interest Rate Estimated Fair Value Asset (Liability) 1-month Term SOFR Loan — 75,000 October 10, 2018 July 1, 2020 June 30, 2025 3.220 % — 421 1-month Term SOFR Loan — 75,000 October 10, 2018 July 1, 2020 June 30, 2025 3.199 % — 502 1-month Term SOFR Loan — 75,000 October 10, 2018 July 1, 2020 June 30, 2025 3.209 % — 403 1-month Term SOFR Loan 100,000 100,000 December 18, 2018 December 30, 2022 December 31, 2027 2.885 % 1,200 3,406 1-month Term SOFR Loan 100,000 100,000 December 18, 2018 December 30, 2022 December 31, 2027 2.867 % 1,264 3,507 1-month Term SOFR Loan 575,000 575,000 December 15, 2020 July 31, 2025 December 31, 2027 1.415 % 25,507 34,537 1-month Term SOFR Loan 125,000 125,000 December 15, 2020 July 1, 2025 December 31, 2027 1.404 % 5,566 7,848 Basis Swap (1) — — March 31, 2023 March 24, 2023 December 31, 2027 N/A ( 1,864 ) ( 1,829 ) $ 900,000 $ 1,125,000 $ 31,673 $ 48,795 (1) The notional of the basis swap amortizes to match the total notional of the interest rate swap portfolio over time The interest rate swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in accumulated other comprehensive income (“AOCI”). For the three and nine months ended September 30, 2025, the Company recorded a gain of $ 1.3 million and a loss of $( 9.6 ) million, respectively, in AOCI related to the change in fair value of the interest rate swaps. For the three and nine months ended September 30, 2024, the Company recorded a loss of $( 17.1 ) million and a gain of $ 2.7 million, respectively, in AOCI related to the change in fair value of the interest rate swaps. 20 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) For the three and nine months ended September 30, 2025, the Company recorded gains of $ 4.6 million and $ 7.5 million, respectively, in the consolidated statements of operations related to the interest rate differential of the interest rate swaps. For the three and nine months ended September 30, 2024, the Company recorded gains of $ 4.1 million and $ 14.4 million, respectively, in the consolidated statements of operations related to the interest rate differential of the interest rate swaps. The estimated gain that is expected to be reclassified to interest income from AOCI as of September 30, 2025 within the next twelve months is $ 16.9 million. The Company has designated these derivative instruments as cash flow hedges. The Company assesses the effectiveness of these derivative instruments and has recorded the changes in the fair value of the derivative instrument designated as a cash flow hedge as unrealized gains or losses in AOCI, net of tax, until the hedged item affected earnings, at which point any gain or loss was reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the remaining amount of any gain or loss on the related cash flow hedge recorded in AOCI to interest expense at that time. Foreign Currency Hedging From time to time, the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company assesses the effectiveness of the contracts that are designated as hedging instruments. The changes in fair value of foreign currency cash flow hedges are recorded in AOCI, net of tax. Those amounts are subsequently reclassified to earnings from AOCI as impacted by the hedged item when the hedged item affects earnings. If the hedged forecasted transaction does not occur or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. For contracts not designated as hedging instruments, the changes in fair value of the contracts are recognized in other income, net in the consolidated statements of operation, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities. The success of the Company’s hedging anticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activities during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect earnings and cash flows. Cross-Currency Rate Swaps The objective of these cross-currency swaps is to reduce volatility of earnings and cash flows associated with changes in the foreign currency exchange rate. Under the terms of these contracts, which have been designated as cash flow hedges, the Company will make interest payments in Swiss francs (“CHFs”) and receive interest in U.S. dollars. Upon the maturity of these contracts, the Company will pay the principal amount of the loans in CHFs and receive U.S. dollars from the counterparties. In December 2020, the Company entered into cross-currency swap agreements to convert a notional amount of $ 471.6 million equivalent to 420.1 million of a CHF-denominated intercompany loan into U.S. dollars. The CHF-denominated intercompany loan was the result of an intra-entity transfer of certain intellectual property rights to a subsidiary in Switzerland completed during the fourth quarter of 2020. The intercompany loan requires quarterly principal payments of CHF 5.8 million plus accrued interest. As a result, the aggregate notional amount of the related cross-currency swaps will decrease by a corresponding amount. In February 2025, the Company amended the CHF-denominated intercompany loan to extend the maturity to December 2030. Concurrently, the Company amended the cross-currency swap agreement, with a notional amount of $ 368.4 million, equivalent to CHF 328.1 million, to extend the maturity to December 2030. 21 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) The Company held the following cross-currency rate swaps as of September 30, 2025 and December 31, 2024 (dollar amounts in thousands): September 30, 2025 December 31, 2024 September 30, 2025 December 31, 2024 Effective Date Termination Date Fixed Rate Aggregate Notional Amount Fair Value Asset (Liability) Pay CHF December 21, 2020 February 19, 2025 3.00 % CHF — 328,136 — ( 4,367 ) Receive U.S.$ 3.98 % $ — 368,362 Pay CHF February 20, 2025 December 20, 2030 3.25 % CHF 310,887 — ( 57,034 ) — Receive U.S.$ 6.14 % $ 348,997 — Total $ ( 57,034 ) $ ( 4,367 ) The cross-currency swaps designated as cash flow hedges are carried on the consolidated balance sheet at fair value, and changes in the fair values are recorded as unrealized gains or losses in AOCI. For the three and nine months ended September 30, 2025, the Company recorded a gain of $ 9.0 million and a loss of $( 40.5 ) million, respectively, in AOCI related to change in fair value of the cross-currency swaps. For the three and nine months ended September 30, 2024, the Company recorded a loss of $( 16.6 ) million and a gain of $ 13.5 million, respectively, in AOCI related to change in fair value of the cross-currency swaps. For the three and nine months ended September 30, 2025, the Company recorded a gain of $ 2.8 million and a loss of $( 47.1 ) million, respectively, in other income, net related to the change in fair value related to the foreign currency rate translation to offset the gains and losses, respectively, recognized on the intercompany loans. For the three and nine months ended September 30, 2024, the Company recorded a loss of $( 23.2 ) million and a gain of $ 5.4 million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the gains and losses, respectively, recognized on the intercompany loans. For the three and nine months ended September 30, 2025, the Company recorded gains of $ 2.3 million and $ 5.7 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three and nine months ended September 30, 2024, the Company recorded gains of $ 1.1 million and $ 3.7 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. The estimated gain that is expected to be reclassified to other income (expense), net from AOCI as of September 30, 2025 within the next twelve months is $ 5.2 million. Net Investment Hedges The Company manages certain foreign exchange risks through a variety of strategies, including hedging. The Company is exposed to foreign exchange risk from its international operations through foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business. In February 2025, the Company entered into a cross-currency swap agreement with a notional amount of CHF 67.8 million equivalent to $ 75.0 million, where the Company agreed with third-parties to sell CHF in exchange for U.S. dollars at a specified rate at the maturity of the contract. The new cross-currency swap agreement was designated as a net investment hedge to partially offset the effects of foreign currency on foreign subsidiaries. On July 25, 2025, the Company entered into a cross-currency swap agreement with a notional amount of CHF 59.7 million, equivalent to $ 75.0 million, where the Company agreed with third-parties to sell CHF in exchange for U.S. dollars at a specified rate at the maturity of the contract. The new cross-currency swap agreement was designated as a net investment hedge to partially offset the effects of foreign currency on foreign subsidiaries. 22 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) The Company held the following cross-currency rate swaps designated as net investment hedges as of September 30, 2025 and December 31, 2024, respectively (dollar amounts in thousands): September 30, 2025 December 31, 2024 September 30, 2025 December 31, 2024 Effective Date Termination Date Fixed Rate Aggregate Notional Amount Fair Value Asset (Liability) Pay EUR October 3, 2018 September 30, 2025 — % EUR 38,820 38,820 — 4,827 Receive U.S.$ 2.19 % $ 45,000 45,000 Pay CHF May 26, 2022 December 16, 2028 — % CHF 240,175 240,175 ( 58,351 ) ( 27,951 ) Receive U.S.$ 1.94 % $ 250,000 250,000 Pay CHF November 17, 2023 December 17, 2029 — % CHF 66,525 66,525 ( 10,982 ) ( 3,248 ) Receive U.S.$ 2.54 % $ 75,000 75,000 Pay CHF May 6, 2024 December 18, 2030 — % CHF 68,483 68,483 ( 12,761 ) ( 4,741 ) Receive U.S.$ 2.74 % $ 75,000 75,000 Pay CHF February 21, 2025 December 15, 2031 — % CHF 67,800 — ( 9,602 ) — Receive U.S.$ 3.24 % $ 75,000 — Pay CHF July 25, 2025 December 15, 2032 — % CHF 59,693 — ( 2,478 ) — Receive U.S.$ 2.66 % $ 75,000 — Total $ ( 94,174 ) $ ( 31,113 ) The cross-currency swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in AOCI. For the three and nine months ended September 30, 2025, the Company recorded a gain of $ 5.0 million and a loss of $( 54.4 ) million, respectively, in AOCI related to the change in fair value of the cross-currency swaps. For the three and nine months ended September 30, 2024, the Company recorded losses of $( 21.1 ) million and $( 0.4 ) million, respectively, in AOCI related to the change in fair value of the cross-currency swaps. For the three and nine months ended September 30, 2025, the Company recorded gains of $ 3.4 million and $ 9.1 million, respectively, in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three and nine months ended September 30, 2024, the Company recorded gains of $ 2.7 million and $ 7.4 million, respectively, in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. The estimated gain that is expected to be reclassified to interest income from AOCI as of September 30, 2025 within the next twelve months is $ 11.4 million. Foreign Currency Forward Contracts The Company has entered into forward contracts designated as cash flow hedges for forecasted purchases in foreign currencies, primarily CHF denominated intercompany purchases. To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are included in accumulated other comprehensive loss. These changes in fair value will be recognized into earnings as a component of cost of sales when the forecasted-transaction occurs. These contracts typically settle at various dates within twelve months of execution. As of September 30, 2025 the notional amount of foreign currency forward contracts was CHF 12.3 million. For the three and nine months ended September 30, 2025, the Company recorded a loss of $( 0.2 ) million and a gain of $ 1.9 million, respectively, in AOCI related to the change in fair value of the foreign currency forward contracts. For the three and nine months ended September 30, 2024, the Company recorded a gain of $ 0.5 million and a loss of $( 0.2 ) million, respectively, in AOCI related to the change in fair value of the foreign currency forward contracts. 23 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) For the three and nine months ended September 30, 2025, the Company recorded an immaterial loss and a loss of $( 0.4 ) million, respectively, in other income and cost of goods sold included in the consolidated statements of operations related to the amortization of forward points and rate translation on the foreign currency forward contracts. For the three and nine months ended September 30, 2024, the Company recorded losses of $( 0.1 ) million and $( 0.3 ) million, respectively, in other income and cost of goods sold included in the consolidated statements of operations related to the amortization of forward points and rate translation on the foreign currency forward contracts. Counterparty Credit Risk The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency. Fair Value of Derivative Instruments The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for the derivative instruments. The fair values of the interest rate swaps and cross-currency swaps were developed using a market approach based on publicly available market yield curves and the terms of the swap. The Company performs ongoing assessments of counterparty credit risk. 24 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of September 30, 2025 and December 31, 2024: Fair Value as of Location on Balance Sheet (1) : September 30, 2025 December 31, 2024 Dollars in thousands Derivatives designated as hedges — Assets: Prepaid expenses and other current assets Cash Flow Hedges Interest rate swap $ 17,999 $ 12,320 Cross-currency swap 3,518 — Foreign currency forward contracts 309 — Net Investment Hedges Cross-currency swap 7,484 8,605 Other assets Cash Flow Hedges Interest rate swap 15,538 38,302 Total derivatives designated as hedges — Assets $ 44,848 $ 59,227 Derivatives designated as hedges — Liabilities: Accrued expenses and other current liabilities Cash Flow Hedges Interest rate swap $ 1,144 $ 684 Cross-currency swap — 4,367 Foreign currency forward contracts — 914 Net Investment Hedges Cross-currency swap 6,670 210 Other liabilities Cash Flow Hedges Interest rate swap 720 1,145 Cross-currency swap 60,552 — Net Investment Hedges Cross-currency swap 94,988 39,507 Total derivatives designated as hedges — Liabilities $ 164,074 $ 46,827 (1) The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months. 25 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying condensed consolidated statement of operations during the three and nine months ended September 30, 2025 and 2024: Dollars in thousands Balance in AOCI Beginning of Quarter Amount of Gain (Loss) Recognized in AOCI Amount of Gain (Loss) Reclassified from AOCI into Earnings Balance in AOCI End of Quarter Location in Statements of Operations Three Months Ended September 30, 2025 Cash Flow Hedges Interest rate swap $ 35,051 $ 1,253 $ 4,629 $ 31,675 Interest expense Cross-currency swap ( 14,767 ) 9,033 5,046 ( 10,780 ) Other income, net Foreign Currency Forward Contract 1,906 ( 162 ) — 1,744 Cost of sales Net Investment Hedges Cross-currency swap ( 96,173 ) 4,955 3,407 ( 94,625 ) Interest income $ ( 73,983 ) $ 15,079 $ 13,082 $ ( 71,986 ) Three Months Ended September 30, 2024 Cash Flow Hedges Interest rate swap $ 53,116 $ ( 17,133 ) $ 4,135 $ 31,848 Interest expense Cross-currency swap ( 16,867 ) ( 16,625 ) ( 22,089 ) ( 11,403 ) Other income, net Foreign Currency Forward Contract $ ( 430 ) $ 474 $ ( 119 ) $ 163 Net Investment Hedges Cross-currency swap ( 29,466 ) ( 21,051 ) 2,739 ( 53,256 ) Interest income $ 6,353 $ ( 54,335 ) $ ( 15,334 ) $ ( 32,648 ) Dollars in thousands Balance in AOCI Beginning of Year Amount of Gain (Loss) Recognized in AOCI Amount of Gain (Loss) Reclassified from AOCI into Earnings Balance in AOCI End of Quarter Location in Statements of Operations Nine Months Ended September 30, 2025 Cash Flow Hedges Interest rate swap $ 48,794 $ ( 9,630 ) $ 7,489 $ 31,675 Interest expense Cross-currency swap ( 11,621 ) ( 40,504 ) ( 41,345 ) ( 10,780 ) Other income (expense), net Foreign currency forward contract ( 624 ) 1,941 ( 427 ) 1,744 Cost of sales Net Investment Hedges Cross-currency swap ( 31,130 ) ( 54,356 ) 9,139 ( 94,625 ) Interest income $ 5,419 $ ( 102,549 ) $ ( 25,144 ) $ ( 71,986 ) Nine Months Ended September 30, 2024 Cash Flow Hedges Interest rate swap $ 43,556 $ 2,678 $ 14,386 $ 31,848 Interest expense Cross-currency swap ( 15,763 ) 13,505 9,145 ( 11,403 ) Other income (expense), net Foreign currency forward contract — $ ( 159 ) $ ( 322 ) 163 Net Investment Hedges Cross-currency swap ( 45,498 ) ( 364 ) 7,394 ( 53,256 ) Interest income $ ( 17,705 ) $ 15,660 $ 30,603 $ ( 32,648 ) Derivative Instruments not Designated Hedges From time to time, the Company enters into foreign currency forward contracts to mitigate risk from the fluctuations in foreign currency exchange rates associated with intercompany balances in Chinese yuan (“CNH”) CHF, and EUR. These contracts typically settle at various dates within twelve months of execution. As of September 30, 2025, the notional amounts totaled CNH 30.0 million and EUR 14.0 million, equivalent to $ 4.1 million, and $ 16.5 million, respectively. 26 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) In 2021, the Company entered into a foreign currency swap, with a notional amount of JPY 800.0 million, equivalent to $ 7.3 million, to mitigate the risk from fluctuations in foreign currency exchange rates associated with an intercompany loan denominated in Japanese yen. In a foreign currency swap transaction, the Company agrees with another party to exchange, at specified intervals, the difference between one currency and another currency at a fixed exchange rate, generally set at inception, calculated by reference to an agreed upon notional amount. The notional amount of each currency is exchanged at the inception and termination of the currency swap by each party. The Company subsequently paid down a portion of this swap, bringing the notional amount down to JPY 400.0 million, equivalent to $ 3.6 million as of September 30, 2025. The fair value of the foreign currency swaps not designated as hedges was $ 0.9 million and $ 1.7 million as of September 30, 2025 and December 31, 2024, respectively. The following table summarizes the gains and losses on derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income: Dollars in thousands Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Foreign currency forward contracts ( 170 ) — ( 1,865 ) — Foreign currency swaps ( 57 ) $ 10 ( 39 ) $ 385 Total $ ( 227 ) $ 10 $ ( 1,904 ) $ 385 8. STOCK-BASED COMPENSATION As of September 30, 2025, the Company had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock unit awards outstanding under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the “2003 Plan”). Stock options issued under the 2003 Plan become exercisable over specified periods, generally within four years from the date of grant for officers and employees, within one year from date of grant for directors which generally expire eight years from the grant date for employees, and from six to ten years for directors and certain executive officers, except in certain instances that result in accelerated vesting due to death, disability, retirement age or change-in-control provisions within their grant agreements. The Company values stock option grants using the binomial distribution model. Restricted stock issued under the 2003 Plan vests over specified periods, generally three years after the date of grant. The vesting of performance stock issued under the 2003 Plan is subject to service and performance conditions. Stock Options As of September 30, 2025, there were approximately $ 4.9 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately three years . There were 395,252 stock options granted during the nine months ended September 30, 2025. For the nine months ended September 30, 2025, the weighted average grant date fair value for stock options granted was $ 10.77 per option. Awards of Restricted Stock and Performance Stock Performance stock and restricted stock awards generally have requisite service periods of three years , except in certain instances that result in accelerated vesting due to death, disability, retirement age provision or change-in-control provisions in their grant agreements. Performance stock units are subject to graded vesting conditions based on revenue goals of the Company. The Company expenses the fair value of restricted stock awards on a straight-line basis over the requisite service period. As of September 30, 2025, there was approximately $ 33.0 million of total unrecognized compensation costs related to these unvested awards. The Company expects to recognize these costs over a weighted-average period of approximately two years . The Company granted 1,012,799 restricted stock awards and 395,781 performance stock awards during the nine months ended September 30, 2025. For the nine months ended September 30, 2025, the weighted average grant date fair value for restricted stock awards and performance stock units granted was $ 21.09 and $ 23.95 per award, respectively. The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan based on its terms. 27 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) 9. RETIREMENT PLANS The Company has various defined benefit plans which cover certain employees in France, Japan, Germany and Switzerland. Net periodic benefit costs for the Company’s defined benefit pension plans for the three and nine months ended September 30, 2025 were $ 0.4 million and $ 1.1 million. The components of the net periodic benefit costs other than the service cost component of $ 0.8 million and $ 2.5 million for the three and nine months ended September 30, 2025 are included in other income, net in the consolidated statements of operations. Net periodic benefit costs for the Company’s defined benefit pension plans for the three and nine months ended September 30, 2024 were $ 0.4 million and $ 1.3 million. The components of the net periodic benefit costs other than the service cost component of $ 0.8 million and $ 2.4 million for the three and nine months ended September 30, 2024 are included in other income, net in the consolidated statements of operations. The estimated fair values of plan assets were $ 61.6 million and $ 51.8 million as of September 30, 2025 and December 31, 2024, respectively. The net plan assets of the pension plans are invested in common trusts as of September 30, 2025 and December 31, 2024. Common trusts are classified as Level 2 in the fair value hierarchy. The fair value of common trusts is valued at the net asset value based on the fair values of the underlying investments of the trusts as determined by the sponsor of the trusts. The investment strategy of the Company’s defined benefit plans is both to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within an appropriate risk profile. Deferred Compensation Plan The Company maintains a deferred compensation plan in which certain employees of the Company may defer the payment and taxation of up to 75 % of their base salary and up to 100 % of bonus amounts and other eligible cash compensation. This deferred compensation is invested in funds offered under this plan and is valued based on Level 1 measurements in the fair value hierarchy. Assets of the Company’s deferred compensation plan are included in other current assets and recorded at fair value based on their quoted market prices. The fair value of these assets were $ 7.6 million and $ 6.7 million as of September 30, 2025 and December 31, 2024, respectively. Offsetting liabilities relating to the deferred compensation plan are included in other liabilities. 10. LEASES AND RELATED PARTY LEASES The Company leases administrative, manufacturing, research and distribution facilities, and vehicles through operating lease agreements. The Company has no finance leases as of September 30, 2025. Many of the Company’s leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common-area or other maintenance costs). For vehicles, the Company has elected the practical expedient to group lease and non-lease components. Most facility leases include one or more options to renew. The exercise of lease renewal options is typically at the Company’s sole discretion, therefore, the majority of renewals to extend the lease terms are not included in the Right of Use (“ROU”) assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates renewal options and when they are reasonably certain of exercise, the renewal period is included in the lease term. As most of the Company’s leases do not provide an implicit rate, the Company uses a collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments. Total operating lease expense for the nine months ended September 30, 2025 and September 30, 2024 was $ 17.8 million and $ 18.8 million, respectively, which includes $ 0.2 million in related party operating lease expense. 28 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) Supplemental balance sheet information related to operating leases were as follows: Dollars in thousands, except lease term and discount rate September 30, 2025 December 31, 2024 ROU assets $ 138,187 $ 144,042 Current lease liabilities 13,826 14,540 Non-current lease liabilities 160,933 166,930 Total lease liabilities $ 174,759 $ 181,470 Weighted average remaining lease term (in years): Leased facilities 16.0 years 16.1 years Leased vehicles 2.8 years 2.3 years Weighted average discount rate: Leased facilities 5.3 % 5.4 % Leased vehicles 3.2 % 2.8 % Supplemental cash flow information related to leases for the nine months ended September 30, 2025 and 2024 were as follows: Dollars in thousands September 30, 2025 September 30, 2024 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 17,729 $ 18,255 ROU assets obtained in exchange for lease liabilities, net of modifications: Operating leases $ 6,493 $ 1,575 Future minimum lease payments under operating leases at September 30, 2025 were as follows: Dollars in thousands Related Parties Third Parties Total Remainder of 2025 $ 74 $ 5,698 $ 5,772 2026 296 17,324 17,620 2027 296 20,620 20,916 2028 296 18,187 18,483 2029 246 17,869 18,115 2030 — 17,642 17,642 Thereafter — 163,525 163,525 Total minimum lease payments $ 1,208 $ 260,865 $ 262,073 Less: Imputed interest 87,314 Total lease liabilities 174,759 Less: Current lease liabilities 13,826 Long-term lease liabilities 160,933 There were no future minimum lease payments under finance leases at September 30, 2025. Related Party Leases The Company leases one of its manufacturing facilities in Plainsboro, New Jersey, from a general partnership that is 50 % owned by a principal stockholder of the Company. The term of the current lease agreement is through October 31, 2029 at an annual rate of approximately $ 0.3 million. The current lease agreement also provides (i) a 5-year renewal option for the Company to extend the lease from November 1, 2029 through October 31, 2034 at the fair market rental rate of the premises, and (ii) another 5-year renewal option to extend the lease from November 1, 2034 through October 31, 2039 at the fair market rental rate of the premises. 29 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) 11. TREASURY STOCK As of September 30, 2025 and December 31, 2024, the company held 14.4 million shares of treasury stock outstanding with a cost of $ 690.0 million and $ 691.4 million, respectively, at a weighted average cost per share of $ 47.86 for both periods. In 2024, the Company entered into a $ 50 million accelerated share repurchase (“the 2024 ASR”) and received 1.3 million shares of common stock at inception of the 2024 ASR, which represented approximately 70 % of the expected total shares under the 2024 ASR. The early exercise provision was exercised by the 2024 ASR counterparty. The Company received an additional 0.4 million shares determined using the volume-weighted average price of the Company’s common stock during the term of the 2024 ASR. On July 18, 2023, the Board of Directors authorized a new $ 225 million share repurchase program. A s of September 30, 2025, $ 50 million remained authorized . The program, which was authorized in July 2023 and expires on December 31, 2025, allows the Company to repurchase its shares opportunistically from time to time. The Company may utilize various methods to effect any repurchases, including open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, including accelerated share repurchases, or a combination of the foregoing, some of which may be effected through Rule 10b5-1 plans. The price and timing of any future purchases under the share repurchase program will depend on factors such as levels of cash generation from operations, the volume of stock option exercises by employees, cash requirements for acquisitions, dividends, economic and market conditions and stock price, and such repurchases may be discontinued at any time. 12. INCOME TAXES The following table provides a summary of the Company’s effective tax rate: Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Reported tax rate 20.8 % 47.5 % 9.3 % 35.3 % The Company’s effective income tax rates for the three months ended September 30, 2025 and 2024 were 20.8 % and 47.5 %, respectively. For the three months ended September 30, 2025, the Company’s effective tax rate was primarily driven by the tax expense generated in certain profitable foreign jurisdictions and the inclusion of Global Intangible Low Taxed Income (“GILTI”); offset by federal, state, and international tax benefits generated from operating losses and favorable prior year tax return positions. For the three months ended September 30, 2024, the tax rate is primarily due to the limitation of foreign tax credits in the U.S. and the limitation of federal tax credits in Switzerland, caused by lower book income. The Company’s effective income tax rates for the nine months ended September 30, 2025 and 2024 were 9.3 % and 35.3 %, respectively. For the nine months ended September 30, 2025, the Company’s effective tax rate was primarily driven by the goodwill impairment charge, as a portion of the charge is non-deductible for tax, as well as the inclusion of GILTI and the global minimum tax in certain foreign jurisdictions; offset by federal, state, and international tax benefits generated from operating losses and favorable prior year tax return positions. For the nine months ended September 30, 2024, the tax rate is primarily due to the limitation of foreign tax credits in the U.S. and the limitation of federal tax credits in Switzerland, caused by lower book income and a $ 1.9 million shortfall from stock-based compensation. Changes to income tax laws and regulations, in any of the tax jurisdictions in which the Company operates, could impact the effective tax rate. Various governments, both U.S. and non-U.S., are increasingly focused on tax reform and revenue-raising legislation. On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the U.S. The OBBBA includes a number of significant provisions, including the permanent extension of certain expiring provisions of the 2017 Tax Cuts and Jobs Act. Additionally, the OBBBA contains changes to the capitalization of research and development expenses, accelerated fixed asset depreciation, and limitations on deductions for interest expense, among other provisions. The Company has evaluated the impact of the OBBBA on its financial statements and estimates the financial impact for the year ended December 31, 2025 to be approximately $ 4.4 million. 30 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) Further, legislation in foreign jurisdictions may be enacted, in continued response to the ongoing base erosion and profit-sharing (“BEPS”) project led by the Organization for Economic Cooperation and Development (“OECD”). The OECD released model rules related to a new 15% global minimum tax regime (“Pillar 2”). A number of the jurisdictions that the Company operates in have adopted some form of the model rules, which became effective beginning in 2024. The Pillar 2 rules are complex and provide for delays for implementing the tax during the early transition years, if certain conditions are met. The Company is calculating an immaterial expense related to Pillar 2 tax liability for the year ending December 31, 2025. Related changes in U.S. and non-U.S. jurisdictions could have an adverse effect on the Company’s effective tax rate. The Company will continue to monitor legislative activity across its U.S. and non-U.S. jurisdictions. 13. NET LOSS PER SHARE Basic and diluted net loss per share was as follows: Three Months Ended September 30, Nine Months Ended September 30, Dollars in thousands, except per share amounts 2025 2024 2025 2024 Basic net loss per share: Net loss $ ( 5,404 ) $ ( 10,695 ) $ ( 514,770 ) $ ( 26,379 ) Weighted average common shares outstanding 76,753 76,448 76,637 77,196 Basic net loss per common share $ ( 0.07 ) $ ( 0.14 ) $ ( 6.72 ) $ ( 0.34 ) Diluted net loss per share: Net loss $ ( 5,404 ) $ ( 10,695 ) $ ( 514,770 ) $ ( 26,379 ) Weighted average common shares outstanding — Basic 76,753 76,448 76,637 77,196 Effect of dilutive securities: Stock options and restricted stock — — — — Weighted average common shares for diluted earnings per share 76,753 76,448 76,637 77,196 Diluted net loss per common share $ ( 0.07 ) $ ( 0.14 ) $ ( 6.72 ) $ ( 0.34 ) Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during the period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, non-vested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. Common stock of approximately 1.5 million and 1.3 million shares at September 30, 2025 and 2024, res pectively, were not included in the computation of diluted net loss per share because their effect would have been anti-dilutive. 14. ACCUMULATED OTHER COMPREHENSIVE LOSS Comprehensive loss for the three and nine months ended September 30, 2025 and 2024: Three Months Ended September 30, Nine Months Ended September 30, Dollars in thousands 2025 2024 2025 2024 Net loss $ ( 5,404 ) $ ( 10,695 ) $ ( 514,770 ) $ ( 26,379 ) Foreign currency translation adjustment ( 1,701 ) 5,386 6,484 ( 2,558 ) Change in unrealized (gain) loss on derivatives, net of tax 800 ( 11,044 ) ( 10,405 ) ( 6,714 ) Pension liability adjustment, net of tax ( 167 ) ( 470 ) ( 483 ) ( 475 ) Comprehensive loss, net $ ( 6,472 ) $ ( 16,823 ) $ ( 519,174 ) $ ( 36,126 ) 31 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) Changes in accumulated other comprehensive loss by component between December 31, 2024 and September 30, 2025 are presented in the table below, net of tax: Dollars in thousands Gains and Losses on Derivatives Defined Benefit Pension Items Foreign Currency Items Total Balance at January 1, 2025 $ 26,612 $ 4,028 $ ( 58,211 ) $ ( 27,571 ) Other comprehensive (loss) gain ( 41,147 ) 13,510 ( 27,637 ) Less: Amounts reclassified from accumulated other comprehensive income, net ( 30,742 ) 483 7,026 ( 23,233 ) Net current-period other comprehensive (loss) gain ( 10,405 ) ( 483 ) 6,484 ( 4,404 ) Balance at September 30, 2025 $ 16,207 $ 3,545 $ ( 51,727 ) $ ( 31,975 ) For the nine months ended September 30, 2025, the Company reclassified losses of $( 35.7 ) million and $( 0.3 ) million from AOCI to other income and cost of goods sold, respectively. Additionally, the Company reclassified a gain of $ 12.8 million from AOCI to interest income. 15. SEGMENT AND GEOGRAPHIC INFORMATION The Company is organized primarily on the basis of products and operates two global reportable segments. Resources are allocated and performance is assessed by the Company’s President and Chief Executive Officer, which the Company has determined to be the Chief Operating Decision Maker (“CODM”). The two reportable segments and their activities are described below. • The Codman Specialty Surgical segment operations consist of (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; (ii) the Instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices; and (iii) the ENT business, which includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, as well as surgical navigation systems. • The Tissue Technologies segment operations consists of Wound Reconstruction and Care business, which sells offerings such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products. The Tissue Technologies segment also includes the Company’s private label business. The Corporate and Other category includes (i) various executive, finance, human resource, information systems and legal functions, (ii) brand management, and (iii) share-based compensation costs, which are not allocated to the reportable segments. For both segments, the CODM uses segment revenue and segment operating income to assess the performance for each segment and in the annual budgeting and forecasting process. The CODM considers budget-to-actual variances on a quarterly basis for segment revenue and segment operating income when making decisions about allocating capital and personnel to the segments. The operating results of the reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the reportable segments. Net sales and profit by each reportable segment for the three and nine months ended September 30, 2025 and 2024 are as follows: 32 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) Three Months Ended September 30, 2025 Nine Months Ended September 30, 2025 Dollars in thousands Codman Specialty Surgical Tissue Technologies Corporate and Other Total Codman Specialty Surgical Tissue Technologies Corporate and Other Total Total revenue, net $ 292,583 $ 109,479 $ — $ 402,062 $ 877,204 $ 323,116 $ — $ 1,200,320 Cost of goods sold 93,289 42,668 59,114 195,071 288,070 138,499 162,996 589,565 Research and development 6,632 4,189 11,635 22,456 22,276 12,243 39,662 74,181 Selling, general & administrative 62,433 35,478 71,135 169,046 201,309 110,283 218,841 530,433 Intangible asset amortization — — 3,728 3,728 — — 11,186 11,186 Goodwill impairment — — — — 388,106 123,259 — 511,365 Total cost and expenses 162,354 82,335 145,612 390,301 899,761 384,284 432,685 1,716,730 Operating income (loss) $ 130,229 $ 27,144 $ ( 145,612 ) 11,761 $ ( 22,557 ) $ ( 61,168 ) $ ( 432,685 ) ( 516,410 ) Interest income 4,982 14,112 Interest expense ( 22,725 ) ( 62,582 ) Other income, net ( 842 ) ( 2,932 ) Loss before income taxes $ ( 6,824 ) $ ( 567,812 ) Three Months Ended September 30, 2024 Nine Months Ended September 30, 2024 Dollars in thousands Codman Specialty Surgical Tissue Technologies Corporate and Other Total Codman Specialty Surgical Tissue Technologies Corporate and Other Total Total revenue, net $ 270,782 $ 110,052 $ — $ 380,834 $ 828,977 $ 338,904 $ — $ 1,167,881 Cost of goods sold 95,829 40,529 44,238 180,596 281,443 119,512 133,937 534,892 Research and development 8,548 4,506 14,381 27,435 21,880 13,858 48,429 84,167 Selling, general & administrative 65,867 36,535 74,791 177,193 157,483 109,199 271,781 538,463 Intangible asset amortization — — 3,760 3,760 — — 17,575 17,575 Total cost and expenses 170,244 81,570 137,170 388,984 460,806 242,569 471,722 1,175,097 Operating income (loss) $ 100,538 $ 28,482 $ ( 137,170 ) ( 8,150 ) $ 368,171 $ 96,335 $ ( 471,722 ) ( 7,216 ) Interest income 5,049 15,147 Interest expense ( 19,373 ) ( 51,648 ) Other income, net 2,112 2,939 Loss before income taxes $ ( 20,362 ) $ ( 40,778 ) The Company does not allocate any assets to the reportable segments. No asset information is reported to the CODM and disclosed in the financial information for each segment. The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following: 33 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) Three Months Ended September 30, Nine Months Ended September 30, Dollars in thousands 2025 2024 2025 2024 United States $ 295,846 $ 290,192 $ 884,371 $ 856,646 Europe 42,893 34,368 120,813 116,653 Asia Pacific 42,680 37,052 135,517 132,548 Rest of World 20,643 19,222 59,619 62,034 Total Revenues $ 402,062 $ 380,834 $ 1,200,320 $ 1,167,881 16. COMMITMENTS AND CONTINGENCIES In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented. In the ordinary course of its business, the Company is involved in, from time to time, various legal actions, including any matters described below, involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, some of which have been settled by the Company. In the opinion of management, such matters are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Company’s financial condition. However, it is possible that the Company’s results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies. The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded and actual results may differ from these estimates. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost. On December 21, 2023, Fortis Advisors, LLC (representative of the security holders of ACell, Inc. (“ACell”)) filed for arbitration against Integra LifeSciences before the Court of International Arbitration of the International Chamber of Commerce claiming breach of contract related to the earnout consideration from the 2021 acquisition of ACell. Refer to the “Contingent Consideration” subheading of this Note for additional information on the ACell contingent consideration. The Company believes that it has strong defenses to the allegations in the arbitration and intends to defend the matter vigorously. On September 12, 2023, a securities class action complaint, captioned Pembroke Pines Firefighters & Police Officers Pension Fund v. Integra LifeSciences Holdings Corporation , No. 23-cv-20321 (D.N.J.), was filed by a purported stockholder of the Company in the United States District Court for the District of New Jersey (the “Pembroke Litigation”) against the Company and certain of the Company’s current and former executive officers. The Pembroke Litigation, filed on behalf of a putative class of stockholders who purchased or acquired the Company’s common stock between March 11, 2019 and May 22, 2023, inclusive, alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder, on the basis of purportedly materially false and misleading statements and omissions relating to certain quality systems issues identified by the FDA at the Company’s Boston facility, the Company’s efforts to remediate those issues, and the Company’s forecasts for certain products in its Tissue Technologies segment. The complaint seeks, among other things, compensatory damages, attorneys’ fees, expert fees, and other costs. The Company believes that it has strong defenses to the allegations in the Pembroke Litigation, and intends to continue to defend the matter vigorously. On July 1, 2025, the class action complaint was dismissed without prejudice. The plaintiffs filed a Second Amended Complaint on August 14, 2025. The Company has filed a motion to dismiss the Second Amended Complaint on October 14, 2025. On February 21, 2025, a derivative lawsuit captioned Grabowsky v. Integra LifeSciences Holding Corp. et al, No. 3:25-cv-01399 (D.N.J.) was filed in the United States District Court for the District of New Jersey. The action purports to assert derivative claims on behalf of the Company against its current Board of Directors and certain of its current or former officers and directors. The action asserts claims that the individual defendants breached their fiduciary duties and harmed the Company by making false and misleading statements and omissions relating to certain quality systems issues identified by the U.S. Food and Drug Administration (“FDA”) at the Company’s Boston facility, the Company’s efforts to remediate those issues, and the Company’s forecasts for certain products in its Tissue Technologies segment. On March 28, 2025, the derivative lawsuit was voluntarily dismissed by the plaintiff. On April 1, 2025 the lawsuit was dismissed with prejudice. 34 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) On May 13, 2025 and May 16, 2025, derivative lawsuits captioned Leverett v. Integra LifeSciences Holding Corp. et al, No. 3:2025-cv-04214 (D.N.J.) and Simpkins v. Integra LifeSciences Holding Corp. et al, No. 3:2025-cv-04446 (D.N.J.) were filed in the United States District Court for the District of New Jersey. The actions purport to assert derivative claims on behalf of the Company against its current Board of Directors and certain of its current or former officers and directors. The actions assert claims that the individual defendants breached their fiduciary duties and harmed the Company by making false and misleading statements and omissions relating to certain quality systems issues identified by the U.S. Food and Drug Administration (“FDA”) at the Company’s Boston, Massachusetts manufacturing facility, the Company’s efforts to remediate those issues, and the Company’s forecasts for certain products in its Tissue Technologies segment. The Company believes that it has strong defenses to the allegations in the lawsuits and intends to defend the matters vigorously. Contingent Consideration The Company determined the fair value of contingent consideration during the nine month period ended September 30, 2025 and September 30, 2024 to reflect the change in estimate, additions, payments, transfers and the time value of money during each period. A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2025 and September 30, 2024 is as follows (in thousands): Nine Months Ended September 30, 2025 Contingent Consideration Liability Related to Acquisition of: Arkis (1) Derma Sciences (2) ACell (2) Surgical Innovations Associates (SIA), Inc. (2) Total Balance as of January 1, 2025 $ 12,968 $ 2,686 $ 3 54,000 69,657 Payment ( 5,000 ) — — ( 18,075 ) ( 23,075 ) Change in fair value of contingent consideration liabilities ( 1,770 ) ( 2,349 ) — ( 10,525 ) ( 14,644 ) Balance as of September 30, 2025 6,198 337 3 25,400 31,938 Short-Term - Accrued expenses and other liabilities $ — $ — $ 3 $ 25,400 $ 25,403 Long-Term - Other liabilities 6,198 337 — — 6,535 Total 6,198 337 3 25,400 31,938 Nine Months Ended September 30, 2024 Contingent Consideration Liability Related to Acquisition of: Arkis (1) Derma Sciences (2) ACell (2) Surgical Innovations Associates (SIA), Inc. (2) Total Balance as of January 1, 2024 $ 15,755 $ 2,557 $ 300 $ 68,700 87,312 Payment ( 12,400 ) ( 12,400 ) Change in fair value of contingent consideration liabilities ( 3,019 ) 137 — 3,100 218 Balance as of September 30, 2024 $ 12,736 $ 2,694 $ 300 $ 59,400 75,130 Short-Term - Accrued expenses and other liabilities $ 8,320 $ — $ — $ 19,600 $ 27,920 Long-Term - Other liabilities 4,416 2,694 300 39,800 47,210 Total 12,736 2,694 300 59,400 75,130 35 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) (1) Location in financial statements: Research and development (2) Location in financial statements: Selling, general and administrative Arkis BioSciences Inc. As part of the acquisition of Arkis BioSciences Inc. (“Arkis”), the Company is required to pay the former shareholders of Arkis up to $ 25.5 million based on the timing of certain development milestones of $ 10.0 million and commercial sales milestones of $ 15.5 million, respectively. The Company used a probability weighted income approach to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specified milestone. The Company estimated the fair value of the contingent consideration to be $ 13.1 million at the acquisition date. In the first quarter of 2025, the Company paid out a development milestone related to design verification procedures for $ 5.0 million. Derma Sciences, Inc. The Company assumed contingent consideration incurred by Derma Sciences, Inc. (“Derma Sciences”) related to its acquisitions of BioD, LLC and the intellectual property related to Medihoney® products. The Company accounted for the contingent liabilities by recording the fair value on the date of the acquisition based on a probability weighted income approach. The Company has already paid $ 33.3 million related to the aforementioned contingent liabilities. One contingent milestone remains, which relates to net sales of Medihoney products exceeding certain amounts defined in the agreement between the Company and Derma Sciences. The potential maximum undiscounted payment amounts to $ 3.0 million. ACell, Inc. As part of the acquisition of ACell, the Company is required to make payments to the former shareholders of ACell up to $ 100.0 million in total for years 2022, 2023, and 2025 based on the achievement by the Company of certain revenue-based performance milestones. The Company estimated the fair value of the contingent consideration to be $ 23.9 million at the acquisition date. The 2022 and 2023 milestones were not achieved, leaving only one contingent milestone remaining. The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specific milestone. Surgical Innovations Associates, Inc. As part of the acquisition of Surgical Innovations Associates, Inc. (“SIA”), the Company is required to pay to the former shareholders of SIA up to $ 90.0 million for two separate payments, which are dependent on (1) achieving certain revenue-based performance milestones in 2023, 2024, and 2025 (up to $ 50.0 million in additional payments), as well as (2) the approval by the FDA of the pre-market approval ("PMA") application for DuraSorb for certain uses by certain timing targets (up to $ 40.0 million in additional payments). The Company estimated the fair value of the contingent consideration for the revenue based milestone to be $ 32.6 million at the acquisition date and $ 25.0 million for the PMA approval milestone at the acquisition date. In the second quarter of 2025, the Company paid out $ 18.1 million related to the 2024 performance year. Similarly, in the second quarter of 2024, the Company paid out $ 12.4 million related to the 2023 performance year. The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration for the revenue-based milestone that considered the possible outcomes of scenarios related to each specific milestone for the revenue based performance milestone. The Company used probabilities of achieving the conditions to calculate the fair value of the contingent consideration for the PMA approval milestone. The liability was adjusted in the third quarter of 2025 due to risk and uncertainty around timing of receiving the PMA approval. 36 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) 17. FAIR VALUE MEASUREMENTS FASB Topic 820, Fair Value Measurement (“ASC 820”) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 establishes a three-level hierarchy of the inputs (i.e., assumptions that market participants would use in pricing an asset or liability) used to measure fair value, giving the highest priority to quoted prices in active markets and the lowest priority to unobservable inputs in measuring fair value. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the entire fair value measurement. The three levels of the valuation hierarchy are defined as follows: Level 1 : Inputs to the valuation methodology are quoted prices in active markets for identical assets or liabilities. Level 2 : Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 : Inputs to the valuation methodology are unobservable inputs that are supported by little or no market activity and are based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company has investments in time deposits that are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices, as well as certain debt obligations that are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The investments in time deposits are classified as cash and cash equivalents and short-term investments on the consolidated balance sheets which is determined based on maturities at the time of purchase and re-evaluated at each balance sheet date. The Company also has investments in derivative instruments, which are comprised of interest rate swaps, cross currency swaps, net investment hedges, and forward foreign currency contracts that are classified within Level 2 of the fair value hierarchy because they are valued using analyses obtained from independent third-party valuation specialists based on market observable inputs. The fair values of these derivative contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 7. Derivative Instruments for further discussion and information on these derivative contracts. In addition, the Company has contingent consideration liabilities that are classified within Level 3 of the fair value hierarchy because they are measured at fair value using significant unobservable inputs, including management’s forecast of future revenues for the acquired businesses as well as management’s estimates of the likelihood of achieving the other specified criteria. Refer to Note 16. Commitments and Contingencies for additional information on these contingent consideration liabilities. 37 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued) Assets and liabilities measured and recorded at fair value on a recurring basis as of September 30, 2025 and December 31, 2024 consisted of the following: Dollars in thousands Fair Value Measurement September 30, 2025 December 31, 2024 Assets: Cash and cash equivalents Level 1 $ 232,186 $ 246,375 Short-term investments Level 1 35,693 27,192 Interest rate swaps Level 2 31,673 48,795 Foreign currency forward contracts Level 2 309 — Foreign currency forward contracts (not designated as hedges) Level 2 933 1,700 Total Assets: $ 300,794 $ 324,062 Liabilities: Cross currency rate swaps Level 2 $ 57,034 $ 4,367 Net investment hedges Level 2 94,174 31,113 Foreign currency forward contracts Level 2 — 914 Contingent consideration Level 3 31,938 69,657 Total Liabilities: $ 183,146 $ 106,051 There were no transfers into or out of Level 3 during the three and nine months ended September 30, 2025 and 2024. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis The Company remeasures the fair value of certain assets and liabilities, including property, plant and equipment, operating lease - right of use assets, and goodwill and other intangible assets, upon the occurrence of certain events. The amounts recognized were recorded to remeasure the carrying amount of assets to the assets’ fair values, which were generally estimated, based upon a market participant’s perspective, using Level 3 measurements, including values estimated using the income approach. Other than the fair value estimates disclosed in Note 2. Acquisitions and Divestitures , Note 5. Goodwill and Other Intangible Assets , and Note 10. Leases and Related Party Leases , there were no non-recurring fair value measurements during the three and nine months ended September 30, 2025 and 2024.